This trial will help researchers learn if FAP-2286 can be used to help identify different types of fibrosis and if it is safe for human use.
4 Primary · 0 Secondary · Reporting Duration: Up to 31 days
Experimental Treatment
30 Total Participants · 3 Treatment Groups
Primary Treatment: 68Ga-FAP-2286 · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: